Company Overview - Xiangsheng Medical's closing price on August 14 was 33.85 yuan, down 2.17%, with a rolling PE ratio of 27.79 times and a total market capitalization of 3.795 billion yuan [1] - The company specializes in the research, manufacturing, and sales of ultrasound medical imaging equipment, and has been recognized as a "Little Giant" enterprise for 2024 by the national government [1] Financial Performance - For Q1 2025, Xiangsheng Medical reported revenue of 128 million yuan, a year-on-year decrease of 9.16%, and a net profit of 41.6145 million yuan, down 8.62% year-on-year, with a gross profit margin of 61.33% [1] Shareholder Information - As of March 31, 2025, the number of shareholders for Xiangsheng Medical was 6,509, an increase of 1,499 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Xiangsheng Medical at the 55th position in the industry ranking [1][2] - The industry average market capitalization is 11.792 billion yuan, while the median is 5.679 billion yuan [2]

A股回购潮此起彼伏！ 10月11日晚间，多家上市公司官宣回购进展，其中亿纬锂能（300014）仅耗时一个月便火速完成回购计 划，累计回购金额达1.5亿元；祥生医疗（688358）更是在4个交易日内一举拿下回购任务，累计斥资 1009万元。另外，三峡水利（600116）、新诺威（300765）、平煤股份（601666）在国庆节后实施首次 回购，宇瞳光学（300790）、精工科技（002006）等回购股份数量已超总股本1%，且近几个交易日斥 资不菲。 积极行动 在回购速度方面，祥生医疗可谓一马当先，从首次实施回购到完成回购，仅用了4个交易日。 今年9月12日，祥生医疗股东会审议通过回购议案，拟斥资1000万元-2000万元以集中竞价交易方式回购 公司股份，回购价格不超过62.05元/股。9月28日，祥生医疗首次回购12.11万股，占总股本的0.108%， 回购价格介于41.48元/股-42.58元/股之间，耗资509.71万元，即首次回购便已完成回购计划下限的50%。 10月11日，距离首次回购仅3个交易日，祥生医疗便宣布完成了回购计划，累计回购24.98万股，占总股 本的0.22%，累计回购金额为1009.47 ...

Core Viewpoint - Xiangsheng Medical (688358) has shown a recent stock price increase of 2.85% to 34.6 yuan, with a trading volume of 18,700 hands and a total transaction amount of 64.49 million yuan as of August 11, 2025 [1] Financial Performance - The company reported a main revenue of 128 million yuan in Q1 2025, a year-on-year decrease of 9.16% - The net profit attributable to shareholders was 41.61 million yuan, down 8.62% year-on-year - The net profit after deducting non-recurring gains and losses was 38.87 million yuan, a decline of 13.38% year-on-year - The debt ratio stands at 9.84%, with investment income of 910,800 yuan and financial expenses of -4.76 million yuan - The gross profit margin is 61.33% [2] Market Position - Xiangsheng Medical's total market value is 3.88 billion yuan, compared to the industry average of 11.897 billion yuan, ranking 94th out of 123 in the medical device industry - The company's net assets are 1.462 billion yuan, below the industry average of 3.899 billion yuan, ranking 86th - The net profit of 41.61 million yuan ranks 46th in the industry, with a price-to-earnings ratio of 23.31, significantly lower than the industry average of 68.73, ranking 16th - The price-to-book ratio is 2.87, compared to the industry average of 3.95, ranking 60th - The company's net profit margin is 32.58%, ranking 13th in the industry, while the return on equity (ROE) is 2.89%, ranking 24th [2] Investment Sentiment - In the last 90 days, one institution has given a buy rating for the stock [3]

Group 1 - The core point of the news is that Xiangsheng Medical has seen an increase in financing buy-in amounts over the past three trading days, indicating growing investor interest [1] - On August 8, Xiangsheng Medical had a financing buy-in amount of 0.14 billion, ranking 1030th in the market, with a financing repayment amount of 0.09 billion, resulting in a net buy of 4.7435 million [1] - Over the last three trading days (August 6-8), the financing buy-in amounts were 0.06 billion, 0.09 billion, and 0.14 billion respectively, showing a consistent upward trend [1] Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold, indicating no activity in this area for Xiangsheng Medical [2]

Core Viewpoint - Xiangsheng Medical (688358.SH) utilizes AI technology through its SonoAI platform to enhance ultrasound clinical applications across various fields, including cardiology, obstetrics, vascular, breast, and bedside applications, achieving a comprehensive upgrade in intelligent scanning, precise measurement, assisted diagnosis, and automated reporting [1] Group 1 - The company’s SonoFamily product line is fully equipped with SonoAI, which features core capabilities such as intelligent lesion recognition, image self-optimization, and diagnostic pathway navigation [1] - The integration of SonoAI allows imaging value to penetrate the entire diagnostic and treatment process [1]

格隆汇8月7日丨祥生医疗(688358.SH)在互动平台表示，公司已布局的超声智能技术，可实现动态图像 识别、疾病自动检测与测量、智能化诊断流程优化及多模态AI融合，建立了覆盖设备研发-影像采集-诊 断决策的智能化标准框架，打造 "精准筛查-智能诊断-个性康复"三位一体服务网络。以"乳 腺人工智能超声机器人"为例，该技术着眼于解决目前国内乳腺癌群体性筛查困境，结合超声、机器人 和人工智能技术，实现大范围的患者筛查入口，逐步形成从筛查到诊断与数据跟踪管理的乳腺健康管理 模式。 ...

Company Overview - Xiangsheng Medical's closing price on August 4 was 33.86 yuan, with a 2.20% increase, resulting in a rolling PE ratio of 27.80, the lowest in 99 days, and a total market value of 3.797 billion yuan [1] - The company specializes in the research, manufacturing, and sales of ultrasound medical imaging equipment, and has been selected as a "Little Giant" enterprise for the 2024 National Specialized and Innovative [1] Financial Performance - For the first quarter of 2025, Xiangsheng Medical reported revenue of 128 million yuan, a year-on-year decrease of 9.16%, and a net profit of 41.6145 million yuan, down 8.62%, with a gross profit margin of 61.33% [1] Industry Comparison - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, placing Xiangsheng Medical at the 55th position in the industry [1] - The company's PE (TTM) is 27.80, while the industry average is significantly higher at 54.32, indicating a potential undervaluation compared to peers [2]

资金流向方面，7月30日主力资金净流出432.93万元，占流通市值的0.12%。 风险提示：股市有风险，投资需谨慎。 来源:金融界 截至2025年7月30日收盘，祥生医疗股价报32.20元，较前一交易日下跌0.28元，跌幅0.86%。当日成交 额0.55亿元，成交量1.7万手，振幅3.20%。 祥生医疗是一家专注于超声医学影像设备研发、生产和销售的企业，产品涵盖全数字超声诊断系统及相 关技术服务。公司所属行业为医疗器械，并涉及人工智能等概念。 ...

Policy Developments - The National Health Commission issued a work plan for the integration of medical and elderly care services, promoting the establishment of national demonstration counties and institutions [2] - The criteria for creating demonstration institutions include operating for over 5 years, a bed occupancy rate of at least 65% in the last 2 years, and over 65% of residents being elderly individuals with disabilities or dementia [2] - The plan emphasizes comprehensive health assessments for the elderly, early intervention for age-related diseases, and the use of traditional Chinese medicine and information technology to enhance service quality [2] Drug and Device Approvals - Humanwell Healthcare announced that its subsidiary received a drug registration certificate for the transdermal patch for treating mild to moderate Alzheimer's disease, with a total R&D investment of approximately RMB 19 million [4] - Kehua Bio received medical device registration certificates for two nucleic acid testing kits, valid until July 16, 2030 [5] Financial Reports - Wohua Pharmaceutical reported a 303.16% year-on-year increase in net profit for the first half of the year, with revenue of RMB 425 million, a 7.64% increase [7] Capital Market Activities - Xiangsheng Medical signed an agreement with the Gates Foundation for the joint development and promotion of innovative obstetric and breast ultrasound screening devices, receiving project funding of USD 2.1 million [9] - Sanofi announced a deal to acquire Vicebio for up to USD 1.6 billion, including an upfront payment of USD 1.15 billion and milestone payments of USD 450 million [11] Industry Developments - The National Medical Insurance Administration reported that from January to June 2025, there were 200 million instances of personal account pooling in employee medical insurance, amounting to RMB 26.177 billion [13]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-018 无锡祥生医疗科技股份有限公司 自愿披露关于与盖茨基金会签署联合开发 基本情况：盖茨基金会（前身 BILL & MELINDA GATES FOUNDATION 即 比尔及梅琳达·盖茨基金会）成立于 2000 年，总部设在美国西雅图。其秉承所有 生命价值平等的信念，致力于将人类的创新才能应用于减少健康和发展领域的不 平等现象。基金会资助新想法，以对抗贫困、疾病以及医疗卫生资源、教育和经 济发展机会短缺等问题，开发并且鼓励新型伙伴关系，确保共有的资源能为最广 泛的人群带来最大的益处。基金会愿景是一个人人都有机会过上健康而富有成效 生活的世界。 二、协议的主要内容 根据协议，盖茨基金会将向公司提供合计 210 万美元的项目资助，以支持公 司开发并推广创新型产科及乳腺超声筛查设备。盖茨基金会将根据项目研发目标 /里程碑的达成情况，按约定的付款时间表分阶段支付项目资金。 该项目产品旨在开发创新型超声解决方案。通过在超声设备上集成智能化的 产前辅助筛查和乳腺病变筛查功能，利用智能化分析盲扫获取的超声视频，实现 智能识别产前及围产期妇女的关键高危妊娠风 ...